Aridis In-Licenses Pneumonia Candidate From AstraZeneca
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has entered into an exclusive, worldwide licensing agreement with AstraZeneca plc (NASDAQ:AZN) to in-license the late-stage monoclonal antibody…
Aridis Pharmaceuticals Announces Exclusive License Of Suvratoxumab Phase 3-Ready Monoclonal Antibody From AstraZeneca; Highlights Uo To $30M Funding From EU Commission For Phase 3 Trial
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (NASDAQ:AZN) to in-license the late stage monoclonal antibody candidate,
China Approves AstraZeneca’s Imfinzi For Extensive-Stage Small Cell Lung Cancer
National Medical Products Administration of China has approved AstraZeneca plc’s (NASDAQ:AZN) Imfinzi (durvalumab) to treat an aggressive type of lung cancer…
AstraZeneca Announced Imfinzi Approved in China for Extensive-stage Small Cell Lung Cancer
AstraZeneca's (NYSE: AZN) Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).
Jon Najarian Sees Unusual Options Activity In AstraZeneca And Home Depot
On CNBC's "Fast Money Halftime Report," Jon Najarian said he saw people buying aggressively the December $60 calls in AstraZeneca plc (NASDAQ: AZN).
Unusual Options Activity Insight: AstraZeneca
AstraZeneca (NASDAQ:AZN) shares experienced unusual options activity on Friday. The stock price moved down to $56.77 following the option alert.
GlaxoSmithKline’s Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE:GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat,…
Why Moderna Shares Are Rallying Today
Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA), which ended Thursday's session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday.